Zhang 10/532690

```
=> d his nofile

     (FILE 'HOME' ENTERED AT 10:48:36 ON 21 NOV 2006)

     FILE 'HCAPLUS' ENTERED AT 10:48:46 ON 21 NOV 2006
                E US2005-532690/APPS
L1            1 SEA ABB=ON  PLU=ON  US2005-532690/AP
                E US2002-423253P/APPS
L2            1 SEA ABB=ON  PLU=ON  US2002-423253P/PRN
                E WO2003-US34185/APPS
L3            1 SEA ABB=ON  PLU=ON  (WO2003-US34185/AP OR WO2003-US34185/PRN)
L*** DEL      0 S NL1-L3
L4            1 SEA ABB=ON  PLU=ON  (L1 OR L2 OR L3)
                D SCAN

     FILE 'REGISTRY' ENTERED AT 10:57:50 ON 21 NOV 2006
                E 4-4-BENZYLOXY-3-CHLOROPHENYL-4-OXOBUTANOIC ACID
                E 4-4-BENZYLOXY-3-CHLOROPHENYL-4-OXOBUTANOIC ACID/CN
                E 4-BENZYLOXY-3-CHLOROPHENYL-4-OXOBUTANOIC ACID/CN

     FILE 'HCAPLUS' ENTERED AT 10:59:07 ON 21 NOV 2006
                SEL RN L4

     FILE 'REGISTRY' ENTERED AT 10:59:17 ON 21 NOV 2006
L5           16 SEA ABB=ON  PLU=ON  (102513-61-1/BI OR 13335-57-4/BI OR
                202577-82-0/BI OR 371251-24-0/BI OR 373596-81-7/BI OR 373596-82
                -8/BI OR 373596-84-0/BI OR 387844-34-0/BI OR 39208-08-7/BI OR
                53090-45-2/BI OR 60525-32-8/BI OR 63539-02-6/BI OR 73083-19-9/B
                I OR 74362-70-2/BI OR 74362-73-5/BI OR 77513-51-0/BI)
                D SCAN
L6            4 SEA ABB=ON  PLU=ON  L5 AND BUTANOIC
                D SCAN

     FILE 'REGISTRY' ENTERED AT 11:07:18 ON 21 NOV 2006
                E BENZENEBUTANOIC ACID/CN
L7            1 SEA ABB=ON  PLU=ON  "BENZENEBUTANOIC ACID, ((3-CHLOROPHENYL)MET
                HYLENE)HYDRAZIDE"/CN
                D SCAN
                E BENZENEBUTANOIC ACID/CN
L8            1 SEA ABB=ON  PLU=ON  "BENZENEBUTANOIC ACID"/CN
                D SCAN
                E BENZENEBUTANOIC ACID/CN
                E BENZYLOXY/CN
L9            1 SEA ABB=ON  PLU=ON  BENZYLOXY/CN
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 11:11:19 ON 21 NOV 2006

     FILE 'REGISTRY' ENTERED AT 11:13:48 ON 21 NOV 2006
L10             STRUCTURE UPLOADED
L11           1 SEA SSS SAM L10

     FILE 'STNGUIDE' ENTERED AT 11:14:04 ON 21 NOV 2006

     FILE 'REGISTRY' ENTERED AT 11:14:29 ON 21 NOV 2006
L12             STRUCTURE UPLOADED
L13           1 SEA SSS SAM L12
L14           8 SEA SSS FUL L12
                D SCAN
```

```
L15           1 SEA ABB=ON  PLU=ON  L5 AND L14
                D SCAN
                SAVE L14 NANCY690/A TEMP
L16           8 SEA ABB=ON  PLU=ON  (L14 OR L15)

     FILE 'HCAPLUS' ENTERED AT 11:16:08 ON 21 NOV 2006
L17           4 SEA ABB=ON  PLU=ON  L16 (L) (THU OR PKT OR DMA OR PAC OR
                BAC)/RL
                D KWIC
                E DIABETES/CT
                E E3+ALL
                E E2+ALL
L18        2178 SEA ABB=ON  PLU=ON  "DIABETES INSIPIDUS"/CT
L19       12931 SEA ABB=ON  PLU=ON  "DIABETES INSIPIDUS"+OLD/CT
                E DIABETES/CT
                E E3+ALL
                E E3+ALL
L20       75871 SEA ABB=ON  PLU=ON  "DIABETES MELLITUS"/CT
                E DIABETES/CT
                E E4+ALL
L21       12931 SEA ABB=ON  PLU=ON  "DIABETES INSIPIDUS"+OLD/CT
                E DIABETES/CT
                E E7+ALL
L22         297 SEA ABB=ON  PLU=ON  "DIABETES INSIPIDUS (L) NEPHROGENIC"/CT
L23      117864 SEA ABB=ON  PLU=ON  ?DIABETES?
                E ATHEROSCLEROSIS/CT
                E E3+ALL
L24       37882 SEA ABB=ON  PLU=ON  ATHEROSCLEROSIS+OLD/CT
                E ATHEROSCLEROSIS/CT
                E ARTERIOSCLEROSIS/CT
                E E3+ALL
L25       41547 SEA ABB=ON  PLU=ON  ARTERIOSCLEROSIS+NT/CT
                E ARTERIOSCLEROSIS/CT
                E E4+ALL
                E OBESITY/CT
                E E3+ALL
L26       28762 SEA ABB=ON  PLU=ON  OBESITY+NT/CT
                E HYPERTENSION/CT
                E E3+ALL
L27       51377 SEA ABB=ON  PLU=ON  HYPERTENSION/CT
                E FATTY LIVER DISEASE/CT
                E E3+ALL
                E E2+ALL
L28       11032 SEA ABB=ON  PLU=ON  "LIVER, DISEASE (L) FATTY"+OLD/CT
                E NEPHROPATHY/CT
                E E3+ALL
                E E2+ALL
L29       40906 SEA ABB=ON  PLU=ON  "KIDNEY, DISEASE"+OLD+NT/CT
L30       68189 SEA ABB=ON  PLU=ON  "KIDNEY, DISEASE"+OLD,NT/CT
                E RETINOPATHY/CT
                E E3+ALL
                E E2+ALL
L31        7915 SEA ABB=ON  PLU=ON  "EYE, DISEASE (L) RETINOPATHY"+OLD/CT
                E FOOT ULCERATION/CT
                E FOOT /CT
                E E+ALL
                E E3+ALL
                E FOOT/CT
                E E3+ALL
```

```
                E ULCERATION/CT
                E CATARACT/CT
                E E3+ALL
L32          5862 SEA ABB=ON  PLU=ON  CATARACT+OLD/CT
                E CATARACT/CT
                E E4+ALL
                E HYPERLIPIDEMIA/CT
                E E3+ALL
L33         11861 SEA ABB=ON  PLU=ON  HYPERLIPIDEMIA+OLD,NT/CT
                E CACHEXIA/CT
                E E3+ALL
L34          2566 SEA ABB=ON  PLU=ON  CACHEXIA/CT
L35        234979 SEA ABB=ON  PLU=ON  FATTY LIVER DISEASE? OR FOOT ULCER? OR
                FEET ULCER? OR INSULIN RESISTANCE? OR OBESITY? OR HYPERLIPIDEMI
                ? OR ATHEROSCLERO? OR ARTERIOSCLER? OR HYPERTENS? OR NEPHROPATH
                ? OR NEUROPATH? OR RETINOPATH? OR CACHEXIA
L36        381179 SEA ABB=ON  PLU=ON  (L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR
                L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR
                L33 OR L34 OR L35)
L37             3 SEA ABB=ON  PLU=ON  L36 AND L17
L38             5 SEA ABB=ON  PLU=ON  L16 AND L36
L39             5 SEA ABB=ON  PLU=ON  (L37 OR L38)
                D KWIC
L40             4 SEA ABB=ON  PLU=ON  L39 NOT L4
                E HODGE K/AU
L41            12 SEA ABB=ON  PLU=ON  ("HODGE K"/AU OR "HODGE KIRVIN L"/AU)
                E SHARMA S/AU
L42          3442 SEA ABB=ON  PLU=ON  ("SHARMA S"/AU OR "SHARMA S A"/AU OR
                "SHARMA S A N"/AU OR "SHARMA S AMITA"/AU OR "SHARMA S B"/AU OR
                "SHARMA S C"/AU OR "SHARMA S C L"/AU OR "SHARMA S CHIDANANDA"/A
                U OR "SHARMA S D"/AU OR "SHARMA S D GURUMAYUM"/AU OR "SHARMA S
                DAS"/AU OR "SHARMA S G"/AU OR "SHARMA S H K"/AU OR "SHARMA S
                J"/AU OR "SHARMA S K"/AU OR "SHARMA S KUMAR"/AU OR "SHARMA S
                L"/AU OR "SHARMA S M"/AU OR "SHARMA S N"/AU OR "SHARMA S P"/AU
                OR "SHARMA S R"/AU OR "SHARMA S RAMA GOPAL"/AU OR "SHARMA S
                S"/AU OR "SHARMA S SEN"/AU OR "SHARMA S SHELLEY"/AU OR "SHARMA
                S SHELLY"/AU OR "SHARMA S V"/AU OR "SHARMA SHALINI"/AU)
                E VON BORSTEL R/AU
L43          114 SEA ABB=ON  PLU=ON  ("VON BORSTEL R"/AU OR "VON BORSTEL R
                C"/AU OR "VON BORSTEL REID"/AU OR "VON BORSTEL REID W"/AU OR
                "VON BORSTEL REID WARREN"/AU)
                E VONBORSTEL R/AU
L44             2 SEA ABB=ON  PLU=ON  "VONBORSTEL REID W"/AU
L45           116 SEA ABB=ON  PLU=ON  (L43 OR L44)
                E WOLPE S/AU
L46            33 SEA ABB=ON  PLU=ON  ("WOLPE S"/AU OR "WOLPE S D"/AU OR "WOLPE
                STEPHEN"/AU OR "WOLPE STEPHEN D"/AU OR "WOLPE STEVE D"/AU OR
                "WOLPE STEVEN"/AU)
L47             7 SEA ABB=ON  PLU=ON  (L41 AND (L42 OR L45 OR L46)) OR (L42 AND
                (L45 OR L46)) OR (L45 AND L46)
L48             4 SEA ABB=ON  PLU=ON  L40 NOT L47

     FILE 'MEDLINE' ENTERED AT 11:28:39 ON 21 NOV 2006

     FILE 'HCAPLUS' ENTERED AT 11:29:02 ON 21 NOV 2006
L49             6 SEA ABB=ON  PLU=ON  (L17 OR L48)
L50             5 SEA ABB=ON  PLU=ON  L49 NOT (L47 OR L4)

     FILE 'MEDLINE' ENTERED AT 11:29:39 ON 21 NOV 2006
```

```
L51             0 SEA ABB=ON  PLU=ON  L16

     FILE 'EMBASE, BIOSIS, CAOLD' ENTERED AT 11:29:56 ON 21 NOV 2006
L52             0 SEA ABB=ON  PLU=ON  L16

     FILE 'WPIX' ENTERED AT 11:30:02 ON 21 NOV 2006
L53             1 SEA SSS FUL L12

     FILE 'REGISTRY' ENTERED AT 11:30:42 ON 21 NOV 2006
                 D BROWSE L15
L54             0 SEA ABB=ON  PLU=ON  74362-73-5/CRN

     FILE 'HCAPLUS' ENTERED AT 11:31:18 ON 21 NOV 2006
L55             2 SEA ABB=ON  PLU=ON  L15
L56             7 SEA ABB=ON  PLU=ON  (L55 OR L50)
L57             6 SEA ABB=ON  PLU=ON  L56 NOT (L47 OR L4)

     FILE 'MEDLINE, EMBASE, BIOSIS, CAOLD' ENTERED AT 11:31:55 ON 21 NOV 2006
L58             0 SEA ABB=ON  PLU=ON  L15

     FILE 'WPIX' ENTERED AT 11:32:13 ON 21 NOV 2006

     FILE 'REGISTRY' ENTERED AT 11:32:24 ON 21 NOV 2006
                 D BROWSE L15

     FILE 'WPIX' ENTERED AT 11:32:39 ON 21 NOV 2006
L59             0 SEA ABB=ON  PLU=ON  BENZENEBUTANOIC ACID/CN
                E BENZENEBUTANOIC ACID, 3-CHLORO-Γ-OXO-4-(PHENYLMETHOXY)-

     FILE 'HCAPLUS' ENTERED AT 11:33:15 ON 21 NOV 2006
L*** DEL        1 S L1
L60             8 SEA ABB=ON  PLU=ON  L16
L61             1 SEA ABB=ON  PLU=ON  L60 NOT (L57 OR L47 OR L1)
L62             1 SEA ABB=ON  PLU=ON  L60 NOT (L57 OR L47 OR L4)
                D KWIC
L63             7 SEA ABB=ON  PLU=ON  (L61 OR L62 OR L57)
L64             0 SEA ABB=ON  PLU=ON  L60 NOT (L63 OR L47 OR L4)

     FILE 'HCAPLUS' ENTERED AT 11:34:17 ON 21 NOV 2006

     FILE 'WPIX' ENTERED AT 11:34:23 ON 21 NOV 2006
                 D QUE L47
                 D QUE L63
                 D QUE L53

     FILE 'STNGUIDE' ENTERED AT 11:34:37 ON 21 NOV 2006

     FILE 'HCAPLUS, WPIX' ENTERED AT 11:34:47 ON 21 NOV 2006
L65            15 DUP REM L47 L63 L53 (0 DUPLICATES REMOVED)
                      ANSWERS '1-14' FROM FILE HCAPLUS
                      ANSWER '15' FROM FILE WPIX

     FILE 'WPIX' ENTERED AT 11:35:04 ON 21 NOV 2006
L66             1 SEA ABB=ON  PLU=ON  L53/DCR
                  SEL SDCN L53
                  EDIT E1 SDCN DCN
L67             1 SEA ABB=ON  PLU=ON  RAECKI/DCN
                  SEL DCSE L53
                  EDIT E2 DCSE DCRE
```

```
L68             0 SEA ABB=ON  PLU=ON  905973-0-0-0/DCRE
L69             1 SEA ABB=ON  PLU=ON  (L67 OR L68)

     FILE 'HCAPLUS' ENTERED AT 11:36:48 ON 21 NOV 2006

     FILE 'WPIX' ENTERED AT 11:36:53 ON 21 NOV 2006
                D QUE L47
                D QUE L63
                D QUE L53
                D QUE L69

     FILE 'STNGUIDE' ENTERED AT 11:37:03 ON 21 NOV 2006

     FILE 'HCAPLUS, WPIX' ENTERED AT 11:37:12 ON 21 NOV 2006
L70            15 DUP REM L47 L63 L53 L69 (1 DUPLICATE REMOVED)
                      ANSWERS '1-14' FROM FILE HCAPLUS
                      ANSWER '15' FROM FILE WPIX
                D IBIB ABS HITIND HITSTR RETABLE L70 1-14
                D IDE L53 TOT
                D ALL ABEQ TECH L70 TOT

     FILE 'WPIX' ENTERED AT 11:38:52 ON 21 NOV 2006
                D ALL ABEQ TECH L69 TOT

     FILE 'REGISTRY' ENTERED AT 12:02:33 ON 21 NOV 2006
                D BROWSE L15

     FILE 'REGISTRY' ENTERED AT 12:02:51 ON 21 NOV 2006
L71             STR 74362-73-5
L72           1 SEA FAM FUL L71
                D SCAN
L73             STRUCTURE UPLOADED
L74           1 SEA SSS SAM L73
L75           8 SEA SSS FUL L73
L76           8 SEA ABB=ON  PLU=ON  (L75 OR L14)


=> file hcaplus
FILE 'HCAPLUS' ENTERED AT 11:36:48 ON 21 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Nov 2006  VOL 145 ISS 22
FILE LAST UPDATED: 20 Nov 2006  (20061120/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

```
 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> file wpix
FILE 'WPIX' ENTERED AT 11:36:53 ON 21 NOV 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED:                          20 NOV 2006   <20061120/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE:     200674      <200674/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
        PLEASE VISIT:
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<


FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf


>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
    PLEASE SEE
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<


>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<
'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d que l47
L41          12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("HODGE K"/AU OR "HODGE
                KIRVIN L"/AU)
L42        3442 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("SHARMA S"/AU OR "SHARMA S
                A"/AU OR "SHARMA S A N"/AU OR "SHARMA S AMITA"/AU OR "SHARMA S
                B"/AU OR "SHARMA S C"/AU OR "SHARMA S C L"/AU OR "SHARMA S
                CHIDANANDA"/AU OR "SHARMA S D"/AU OR "SHARMA S D GURUMAYUM"/AU
                OR "SHARMA S DAS"/AU OR "SHARMA S G"/AU OR "SHARMA S H K"/AU
                OR "SHARMA S J"/AU OR "SHARMA S K"/AU OR "SHARMA S KUMAR"/AU
                OR "SHARMA S L"/AU OR "SHARMA S M"/AU OR "SHARMA S N"/AU OR
                "SHARMA S P"/AU OR "SHARMA S R"/AU OR "SHARMA S RAMA GOPAL"/AU
                OR "SHARMA S S"/AU OR "SHARMA S SEN"/AU OR "SHARMA S SHELLEY"/A
                U OR "SHARMA S SHELLY"/AU OR "SHARMA S V"/AU OR "SHARMA
                SHALINI"/AU)
L43         114 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("VON BORSTEL R"/AU OR "VON
                BORSTEL R C"/AU OR "VON BORSTEL REID"/AU OR "VON BORSTEL REID
                W"/AU OR "VON BORSTEL REID WARREN"/AU)
L44           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "VONBORSTEL REID W"/AU
L45         116 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L43 OR L44)
L46          33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WOLPE S"/AU OR "WOLPE S
                D"/AU OR "WOLPE STEPHEN"/AU OR "WOLPE STEPHEN D"/AU OR "WOLPE
```

```
                STEVE D"/AU OR "WOLPE STEVEN"/AU)
L47           7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L41 AND (L42 OR L45 OR L46))
                OR (L42 AND (L45 OR L46)) OR (L45 AND L46)


=> d que 163
L1            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2005-532690/AP
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2002-423253P/PRN
L3            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (WO2003-US34185/AP OR
                WO2003-US34185/PRN)
L4            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L1 OR L2 OR L3)
L5           16 SEA FILE=REGISTRY ABB=ON  PLU=ON  (102513-61-1/BI OR 13335-57-4
                /BI OR 202577-82-0/BI OR 371251-24-0/BI OR 373596-81-7/BI OR
                373596-82-8/BI OR 373596-84-0/BI OR 387844-34-0/BI OR 39208-08-
                7/BI OR 53090-45-2/BI OR 60525-32-8/BI OR 63539-02-6/BI OR
                73083-19-9/BI OR 74362-70-2/BI OR 74362-73-5/BI OR 77513-51-0/B
                I)
L12             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L14           8 SEA FILE=REGISTRY SSS FUL L12
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND L14
L16           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L14 OR L15)
L17           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 (L) (THU OR PKT OR DMA OR
                PAC OR BAC)/RL
L18        2178 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DIABETES INSIPIDUS"/CT
L19       12931 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DIABETES INSIPIDUS"+OLD/CT
L20       75871 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DIABETES MELLITUS"/CT
L21       12931 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DIABETES INSIPIDUS"+OLD/CT
L22         297 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "DIABETES INSIPIDUS (L)
                NEPHROGENIC"/CT
L23      117864 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ?DIABETES?
L24       37882 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ATHEROSCLEROSIS+OLD/CT
L25       41547 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ARTERIOSCLEROSIS+NT/CT
```

```
L26       28762 SEA FILE=HCAPLUS ABB=ON  PLU=ON  OBESITY+NT/CT
L27       51377 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HYPERTENSION/CT
L28       11032 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "LIVER, DISEASE (L) FATTY"+OLD
                /CT
L29       40906 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "KIDNEY, DISEASE"+OLD+NT/CT
L30       68189 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "KIDNEY, DISEASE"+OLD,NT/CT
L31        7915 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "EYE, DISEASE (L) RETINOPATHY"
                +OLD/CT
L32        5862 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CATARACT+OLD/CT
L33       11861 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HYPERLIPIDEMIA+OLD,NT/CT
L34        2566 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CACHEXIA/CT
L35      234979 SEA FILE=HCAPLUS ABB=ON  PLU=ON  FATTY LIVER DISEASE? OR FOOT
                ULCER? OR FEET ULCER? OR INSULIN RESISTANCE? OR OBESITY? OR
                HYPERLIPIDEMI? OR ATHEROSCLERO? OR ARTERIOSCLER? OR HYPERTENS?
                OR NEPHROPATH? OR NEUROPATH? OR RETINOPATH? OR CACHEXIA
L36      381179 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L18 OR L19 OR L20 OR L21 OR
                L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR
                L31 OR L32 OR L33 OR L34 OR L35)
L37           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L36 AND L17
L38           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 AND L36
L39           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L37 OR L38)
L40           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L39 NOT L4
L41          12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("HODGE K"/AU OR "HODGE
                KIRVIN L"/AU)
L42        3442 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("SHARMA S"/AU OR "SHARMA S
                A"/AU OR "SHARMA S A N"/AU OR "SHARMA S AMITA"/AU OR "SHARMA S
                B"/AU OR "SHARMA S C"/AU OR "SHARMA S C L"/AU OR "SHARMA S
                CHIDANANDA"/AU OR "SHARMA S D"/AU OR "SHARMA S D GURUMAYUM"/AU
                OR "SHARMA S DAS"/AU OR "SHARMA S G"/AU OR "SHARMA S H K"/AU
                OR "SHARMA S J"/AU OR "SHARMA S K"/AU OR "SHARMA S KUMAR"/AU
                OR "SHARMA S L"/AU OR "SHARMA S M"/AU OR "SHARMA S N"/AU OR
                "SHARMA S P"/AU OR "SHARMA S R"/AU OR "SHARMA S RAMA GOPAL"/AU
                OR "SHARMA S S"/AU OR "SHARMA S SEN"/AU OR "SHARMA S SHELLEY"/A
                U OR "SHARMA S SHELLY"/AU OR "SHARMA S V"/AU OR "SHARMA
                SHALINI"/AU)
L43         114 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("VON BORSTEL R"/AU OR "VON
                BORSTEL R C"/AU OR "VON BORSTEL REID"/AU OR "VON BORSTEL REID
                W"/AU OR "VON BORSTEL REID WARREN"/AU)
L44           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "VONBORSTEL REID W"/AU
L45         116 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L43 OR L44)
L46          33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WOLPE S"/AU OR "WOLPE S
                D"/AU OR "WOLPE STEPHEN"/AU OR "WOLPE STEPHEN D"/AU OR "WOLPE
                STEVE D"/AU OR "WOLPE STEVEN"/AU)
L47           7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L41 AND (L42 OR L45 OR L46))
                OR (L42 AND (L45 OR L46)) OR (L45 AND L46)
L48           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L40 NOT L47
L49           6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L17 OR L48)
L50           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L49 NOT (L47 OR L4)
L55           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L15
L56           7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L55 OR L50)
L57           6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L56 NOT (L47 OR L4)
L60           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16
L61           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L60 NOT (L57 OR L47 OR L1)
L62           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L60 NOT (L57 OR L47 OR L4)
L63           7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L61 OR L62 OR L57)


=> d que 153
L12             STR
```



Structure attributes must be viewed using STN Express query preparation.
L53 1 SEA FILE=WPIX SSS FUL L12

=> d que l69
L67 1 SEA FILE=WPIX ABB=ON PLU=ON RAECKI/DCN
L68 0 SEA FILE=WPIX ABB=ON PLU=ON 905973-0-0-0/DCRE
L69 1 SEA FILE=WPIX ABB=ON PLU=ON (L67 OR L68)

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 11:37:03 ON 21 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 17, 2006 (20061117/UP).

=> dup rem l47,l63,l53,l69
FILE 'HCAPLUS' ENTERED AT 11:37:12 ON 21 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 11:37:12 ON 21 NOV 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
PROCESSING COMPLETED FOR L47
PROCESSING COMPLETED FOR L63
PROCESSING COMPLETED FOR L53
PROCESSING COMPLETED FOR L69
L70 15 DUP REM L47 L63 L53 L69 (1 DUPLICATE REMOVED)
ANSWERS '1-14' FROM FILE HCAPLUS

ANSWER '15' FROM FILE WPIX

=> d ibib abs hitind hitstr retable l70 1-14;d ide l53 tot ;d all abeq tech l70 tot

L70 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:412751 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 140:400084
TITLE: Oxocarboxylic acids and esters thereof for the treatment of metabolic disorders
INVENTOR(S): ***Hodge, Kirvin L.; Sharma, Shalini; Von Borstel, Reid W.; Wolpe, Stephen D.***
PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA; Von Borstel, Reid W.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041165	A2	20040521	WO 2003-US34185	20031028
WO 2004041165	A3	20050203		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502297	AA	20040521	CA 2003-2502297	20031028
AU 2003286728	A1	20040607	AU 2003-286728	20031028
EP 1556085	A2	20050727	EP 2003-777939	20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507303	T2	20060302	JP 2004-550151	20031028
US 2006035970	A1	20060216	US 2005-532690	20050426

PRIORITY APPLN. INFO.: US 2002-423253P P 20021101
WO 2003-US34185 W 20031028

AB Oxocarboxylic acids and esters thereof are disclosed which are useful for the treatment of various metabolic disorders, e.g. insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.
IC ICM A61K
CC 1-10 (Pharmacology)

L70 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:177884 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 142:279944
TITLE: Preparation of phenyl thioethers for the treatment of metabolic disorders
INVENTOR(S): ***Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.***
PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA

SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018628	A1	20050303	WO 2004-US26561	20040816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004266673	A1	20050303	AU 2004-266673	20040816
CA 2533890	AA	20050303	CA 2004-2533890	20040816
EP 1656127	A1	20060517	EP 2004-781277	20040816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1835743	A	20060920	CN 2004-80023552	20040816
NO 2006000502	A	20060503	NO 2006-502	20060131

PRIORITY APPLN. INFO.: US 2003-496533P P 20030820
WO 2004-US26561 W 20040816

OTHER SOURCE(S): CASREACT 142:279944; MARPAT 142:279944

GI



I



II

AB The title compds. I [n = 1-2; m, q, t = 0-1; R5 = alkyl; R9 = H, halo,

alkyl, alkoxy; A = (un)substituted Ph, cycloalkyl, 5-6 membered heteroarom. ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroarom. ring is covalently bound to the remainder of the compound I by a ring carbon; X = CH2; Q = OR1 and R1 = Me, Et; or X = CH2CR12R13 or CH2CH(NHAc) (wherein R12, R13 = H, Me), Q = OR1 and R1 = H, alkyl; or X = CH2CH2 and Q = NR10R11 (wherein one of R10 and R11 = H, alkyl or OH, and the other = H); alternatively, when R1 = H, the biol. active agent can be a pharmaceutically acceptable salt of the compound I], useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. E.g., a multi-step synthesis of II, starting from 2,6-dimethylbenzyl alc., was given. The pharmaceutical composition comprising the compound I is also disclosed.

IC ICM A61K031-19
ICS A61K031-235; C07C323-00

CC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Sharma	2002			WO 02100341 A2	HCAPLUS

L70 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:962218 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 143:266913
TITLE: Preparation of 3-pyrazolecarboxamide derivatives as CB1 receptor modulators for the treatment of ***obesity*** and other diseases
INVENTOR(S): Cheng, Leifeng; Lindstedt-Alstermark, Eva-Lotte; Boije, Anna Maria Persdotter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080343	A2	20050901	WO 2005-GB534	20050216
WO 2005080343	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214130	A1	20050901	AU 2005-214130	20050216
CA 2555331	AA	20050901	CA 2005-2555331	20050216
EP 1718617	A2	20061108	EP 2005-717730	20050216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

NO 2006003787 A 20060919 NO 2006-3787 20060824

PRIORITY APPLN. INFO.: GB 2004-3779 A 20040220
GB 2004-20780 A 20040918
WO 2005-GB534 W 20050216

OTHER SOURCE(S): MARPAT 143:266913

GI



I



II

AB The title compds. I [R1 = substituted alkoxy, sulfonyl, sulfonamide or silanyl; Ra = halo, alkyl or alkoxy; m, n = 0-3; R2 = alkyl, alkoxy, etc.; R3 = substituted aminocarbonyl, etc.; R4 = H, alkyl, etc., with two exclusions, and pharmaceutically acceptable salts thereof] were prepared as CB1 receptor modulators. As an example, II was synthesized via sulfonylation of the corresponding phenol (preparation given) with n-PrSO2Cl in 49% yield. I are active in the CB1 receptor with IC50 values of < 1 μM (IC50 = 6 nM for II) and believed to be selective CB1 antagonists or inverse agonists. Therefore, I and their pharmaceutical compns. may be used in the treatment of ***obesity***, psychiatric disorders, neurol. disorders and so on.

IC ICM C07D231-00

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST pyrazolecarboxamide prepn ***obesity*** psychiatric neurol disorder treatment; CB1 receptor modulator pyrazole carboxamide prepn

IT Nervous system, disease
(Huntington's chorea, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

IT Mental and behavioral disorders
(attention deficit disorder, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

IT Mental and behavioral disorders
(bipolar disorder, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other

diseases)
IT Mental and behavioral disorders
(dementia, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Mental and behavioral disorders
(depression, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Mental and behavioral disorders
(obsession-compulsion, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Anti-Alzheimer's agents
Anticonvulsants
Antidepressants
Antiobesity agents
Antiparkinsonian agents
Antipsychotics
Anxiolytics
Cardiovascular agents
Cognition enhancers
Immunomodulators
Nervous system agents
(preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Mental and behavioral disorders
(psychosis, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Shock (circulatory collapse)
(septic, treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Alzheimer's disease
Anorexia
Anxiety
Cardiovascular system, disease
Cognitive disorders
Digestive tract, disease
Drug dependence
Endocrine system, disease
Epilepsy
Immune disease
Memory disorders
Mental and behavioral disorders
Nervous system, disease
Obesity
Parkinson's disease
Reproduction disorders
Respiratory system, disease
Schizophrenia
(treatment of; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB1, modulator; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)
IT 863639-64-9P 863639-65-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazolecarboxamides CB1 receptor modulators

for treatment of ***obesity*** and other diseases)

IT 863639-38-7P 863639-39-8P 863639-40-1P 863639-41-2P 863639-43-4P
863639-44-5P 863639-46-7P 863639-52-5P 863639-56-9P 863639-58-1P
863639-61-6P 863639-62-7P 863639-63-8P 863639-66-1P 863639-67-2P
863639-68-3P 863639-69-4P 863639-72-9P 863639-73-0P 863639-78-5P
863639-79-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

IT 52-52-8, 1-Aminocyclopentanecarboxylic acid 70-70-2 95-92-1, Oxalic acid diethyl ester 100-39-0, Benzyl bromide 109-61-5, Propyl chloroformate 110-73-6, 2-(Ethylamino)ethanol 141-97-9, Ethyl acetoacetate 443-93-6 461-17-6, 1-Iodo-4,4,4-trifluorobutane 554-00-7, 2,4-Dichloroaniline 2213-43-6, 1-Aminopiperidine 2386-60-9, Butanesulfonyl chloride 2766-74-7, 5-Chlorothiophene-2-sulfonyl chloride 4319-49-7, 4-Aminomorpholine 10147-36-1, 1-Propanesulfonyl chloride 10307-18-3 13123-92-7, (2,4-Dichlorophenyl)hydrazine 16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl chloride 18742-02-4, 2-(2-Bromoethyl)-1,3-dioxolane 22795-37-5, 3-Methylbutane-1-sulfonyl chloride 54696-05-8, 1-(4-Benzyloxyphenyl)ethanone 63234-70-8, 1-Aminopiperidine hydrochloride 74784-70-6, 5-(Trifluoromethyl)pyridin-2-amine 178374-78-2 212190-25-5 845866-80-0 863639-75-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

IT 4495-66-3P 35081-45-9P 57696-12-5P 60421-23-0P, Methyl 1-aminocyclopentanecarboxylate hydrochloride 152192-95-5P 178374-92-0P
178374-93-1P 502486-92-2P 503270-34-6P 863639-35-4P 863639-36-5P
863639-37-6P 863639-42-3P ***863639-47-8P*** 863639-48-9P
863639-49-0P 863639-50-3P 863639-51-4P 863639-53-6P 863639-54-7P
863639-55-8P 863639-57-0P 863639-59-2P 863639-60-5P 863639-70-7P
863639-71-8P 863639-74-1P 863639-76-3P 863639-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

IT ***863639-47-8P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolecarboxamides CB1 receptor modulators for treatment of ***obesity*** and other diseases)

RN 863639-47-8 HCAPLUS
CN Benzenebutanoic acid, α-acetyl-3,5-difluoro-β-methyl-γ-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



L70 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:995903 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 141:410698
TITLE: Preparation of α-oxoacid-substituted phenols for the treatment of metabolic disorders
INVENTOR(S): ***Hodge, Kirvin L.; Sharma, Shalini; Von Borstel, Reid W.***
PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA; Von Borstel, Reid W.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098496	A2	20041118	WO 2004-US12141	20040420
WO 2004098496	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004237602	A1	20041118	AU 2004-237602	20040420
CA 2522738	AA	20041118	CA 2004-2522738	20040420
EP 1617835	A2	20060125	EP 2004-750363	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1780614	A	20060531	CN 2004-80011552	20040420
JP 2006525331	T2	20061109	JP 2006-513150	20040420

PRIORITY APPLN. INFO.: US 2003-466663P P 20030430
WO 2004-US12141 W 20040420

OTHER SOURCE(S): CASREACT 141:410698; MARPAT 141:410698
GI



I

AB Title compds. I [n = 1-2; m = 0-4; q, p = 0-1; R2 = alkyl; R3 = H, halo; A = (un)substituted Ph, cycloalkyl, etc.; R1 = H, alkyl] are prepared For instance, 2-oxo-2-[3-(2,6-dimethylbenzyloxy)phenyl]acetic acid (II) is prepared by SeO2 oxidation of the corresponding ethanone precursor (prior art). II showed a statistically significant decrease in blood glucose and triglycerides in obese mice compared to control at 60 mg/Kg. I are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

IC ICM A61K

CC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

L70 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:927013 HCAPLUS <<LOGINID::20061121>>

DOCUMENT NUMBER: 141:395291

TITLE: Preparation of benzyloxyphenyl acids and related compounds for the treatment of metabolic disorders

INVENTOR(S): ***Hodge, Kirvin L.***; Kaufman, Robert J.; Lee, Albert; ***Sharma, Shalini***; ***Von Borstel, Reid W.***

PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA

SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093806	A2	20041104	WO 2004-US12142	20040420
WO 2004093806	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521589	AA	20041104	CA 2004-2521589	20040420
EP 1618086	A2	20060125	EP 2004-750364	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1777576	A	20060524	CN 2004-80010732	20040420
JP 2006524252	T2	20061026	JP 2006-513151	20040420

PRIORITY APPLN. INFO.: US 2003-464553P P 20030422
WO 2004-US12142 W 20040420

OTHER SOURCE(S): MARPAT 141:395291

GI



I



II

AB Title compds. I [Z = (CH2)n(NR3)q(CH2)tA; X = (CH2)m; R1 = H, alkyl; R2 = alkyl; R3 = H, halo, alkyl, etc.; n = 1-2; m = 2-3; q = 0-1; t = 0-1; A = (un)substituted Ph, cycloalkyl, heteroarom., etc.] and their pharmaceutically acceptable salts were prepared For example, condensation of 3-(2,6-dimethylbenzyloxy)benzaldehyde and triphenylethylbutyrate phosphonium bromide afforded claimed benzyloxyphenyl acid ester II in 62% yield. In serum glucose assays in b/db mice, compound II exhibited glucose mg/dL of 651 at 100 mg/kg dosage. Compds. I are claimed useful for the treatment of metabolic disorders, i.e., diabetes, metabolic syndrome X, obesity, etc.

IC ICM A61K

CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

L70 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:902090 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 141:384282
TITLE: Compounds for the treatment of metabolic disorders
INVENTOR(S): ***Hodge, Kirvin L.; Sharma, Shalini; Von Borstel, Reid W.; Wolpe, Stephen D.***
PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091486	A2	20041028	WO 2004-US10799	20040408
WO 2004091486	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004229418	A1	20041028	AU 2004-229418	20040408
CA 2521621	AA	20041028	CA 2004-2521621	20040408
EP 1633340	A2	20060315	EP 2004-759257	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009469	A	20060418	BR 2004-9469	20040408
CN 1774244	A	20060517	CN 2004-80010105	20040408
JP 2006523696	T2	20061019	JP 2006-509802	20040408
US 2006014784	A1	20060119	US 2005-531618	20050414
NO 2005004791	A	20051220	NO 2005-4791	20051018
PRIORITY APPLN. INFO.:			US 2003-462960P P	20030415
			WO 2004-US10799 W	20040408

OTHER SOURCE(S): MARPAT 141:384282

AB Agents such as 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-hydroxybutanoic acid, useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Thus, 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-(R)-hydroxybutanoic acid was prepared by the NaBH4 reduction of 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutanoic acid. The above compound elicited a significant reduction in blood glucose.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

L70 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:718293 HCAPLUS <<LOGINID::20061121>>

DOCUMENT NUMBER: 141:236676

TITLE: Compounds for the treatment of metabolic disorders

INVENTOR(S): ***Hodge, Kirvin L.***; Lee, Albert; ***Sharma, Shalini***; ***Von Borstel, Reid W.***

PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA

SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073611	A2	20040902	WO 2004-US3718	20040209
WO 2004073611	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212905	A1	20040902	AU 2004-212905	20040209
CA 2513092	AA	20040902	CA 2004-2513092	20040209
EP 1601251	A2	20051207	EP 2004-709467	20040209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2004007506	A	20060214	BR 2004-7506		20040209
CN 1750758	A	20060322	CN 2004-80004150		20040209
JP 2006517920	T2	20060803	JP 2005-518490		20040209
US 2006247309	A1	20061102	US 2005-531630		20050414
NO 2005003211	A	20051020	NO 2005-3211		20050630
PRIORITY APPLN. INFO.:			US 2003-447168P	P	20030213
			WO 2004-US3718	W	20040209

OTHER SOURCE(S): MARPAT 141:236676

AB Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R2 is alkyl from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is Ph, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstituted or one or two ring carbons are independently mono-substituted by Me or ethyl; or a 5 or 6 membered heteroarom. ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroarom. ring is covalently bound to the remainder of the compds. of formula (I) by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biol. active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

IC ICM A61K

CC 1-10 (Pharmacology)
Section cross-reference(s): 25

L70 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:696360 HCAPLUS <<LOGINID::20061121>>

DOCUMENT NUMBER: 141:225492

TITLE: Preparation of isoxazoles as inhibitors of heat shock proteins

INVENTOR(S): Drysdale, Martin James; Dymock, Brian William; Finch, Harry; Webb, Paul; Mcdonald, Edward; James, Karen Elizabeth; Cheung, Kwai Ming; Mathews, Thomas Peter

PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK; Cancer Research Technology Ltd; The Institute of Cancer Research; et al.; et al.

SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072051	A1	20040826	WO 2004-GB506	20040209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210779	A1	20040826	AU 2004-210779	20040209

CA 2515726	AA	20040826	CA 2004-2515726		20040209
EP 1611112	A1	20060104	EP 2004-709273		20040209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1771235	A	20060510	CN 2004-80009339		20040209
JP 2006517572	T2	20060727	JP 2006-502254		20040209
BR 2004007403	A	20061003	BR 2004-7403		20040209
NO 2005004195	A	20051109	NO 2005-4195		20050909
US 2006241106	A1	20061026	US 2006-544443		20060421
PRIORITY APPLN. INFO.:			GB 2003-3105	A	20030211
			GB 2003-6560	A	20030321
			GB 2003-13751	A	20030613
			WO 2004-GB506	W	20040209

OTHER SOURCE(S): MARPAT 141:225492

GI



I



II

AB Title compds. [I, II; R1 = Ar1(Alk1)p(Z)r(Alk2)sQ; Ar1 = (substituted) aryl, heteroaryl; Alk1, Alk2 = (substituted) alkylene, alkenylene; p, r, s = 0, 1; Z = O, S, CO, CS, SO2, CO2, CONRA, CSNRA, SO2NRA, NRACO, NRASO2, NRA; RA = H, alkyl; Q = H, (substituted) carbocyclyl, heterocyclyl; R2 = Ar1(Alk1)p(Z)r(Alk2)sQ, carboxamide, carbocyclyl, heterocyclyl optionally substituted by (Alk1)pZr(Alk2)sQ; R3 = H, (substituted) cycloalkyl, cycloalkenyl, alkyl, alkenyl, alkynyl, carboxyl, carboxamide, carboxyl ester], were prepared Thus, NH2OH.HCl and 7-hydroxy-3-(4-methoxyphenyl)-2-methylchromen-4-one (preparation given) were refluxed 4 h in pyridine to give 4-[4-(4-methoxyphenyl)-3-methylisoxazol-5-yl]benzene-1,3-diol. The latter in the Malachite Green ATPase assay inhibited HSP90 with IC50 <50 μM.

IC ICM C07D261-08
ICS C07D413-04; C07D413-10; C07D417-04; C07D261-10; C07D495-04; A61P035-00

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT ***Eye, disease***
(diabetic ***retinopathy***, treatment; preparation of isoxazoles as inhibitors of heat shock proteins)

IT Autoimmune disease
(insulin-dependent ***diabetes*** mellitus, treatment; preparation of isoxazoles as inhibitors of heat shock proteins)

IT ***Diabetes mellitus***
(insulin-dependent, treatment; preparation of isoxazoles as inhibitors of heat shock proteins)

IT 487-49-0P 2284-30-2P 13004-42-7P 19337-03-2P 22877-01-6P
23504-03-2P 29048-54-2P 90110-32-0P 103620-87-7P 130307-08-3P
140660-31-7P 328018-52-6P 536974-86-4P 558645-35-5P 705963-54-8P
747412-81-3P 747412-82-4P 747412-94-8P 747413-00-9P
747413-03-2P 747413-04-3P 747413-05-4P 747413-06-5P
747413-07-6P 747413-12-3P 747413-16-7P 747413-17-8P 747413-18-9P
747413-19-0P 747413-21-4P 747413-22-5P 747413-23-6P 747413-31-6P
747413-33-8P 747413-34-9P 747413-35-0P 747413-68-9P

747413-69-0P 747413-70-3P 747413-71-4P 747413-72-5P
747413-73-6P 747413-74-7P 747413-75-8P 747414-06-8P 747414-07-9P
747414-08-0P 747414-09-1P 747414-10-4P 747414-11-5P 747414-12-6P
747414-16-0P 747414-17-1P 747414-18-2P 747414-19-3P 747414-20-6P
747414-21-7P 747414-22-8P 747414-23-9P 747414-24-0P 747414-48-8P
747414-49-9P 747414-50-2P 747414-51-3P 747414-52-4P 747414-53-5P
747414-55-7P 747414-56-8P 747414-57-9P 747414-62-6P 747414-63-7P
747414-64-8P 747414-65-9P 747414-66-0P 747414-67-1P 747414-69-3P
747414-70-6P 747414-71-7P 747414-72-8P 747414-73-9P
747414-74-0P 747414-76-2P 747414-78-4P 747414-79-5P 747414-80-8P
747414-84-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazoles as inhibitors of heat shock proteins)

IT ***747413-03-2P 747413-69-0P 747414-70-6P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazoles as inhibitors of heat shock proteins)

RN 747413-03-2 HCAPLUS
CN 2-Butenoic acid, 4-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-2-hydroxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 747413-69-0 HCAPLUS
CN Benzenebutanoic acid, 5-bromo-α,γ-dioxo-2,4-bis(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 747414-70-6 HCAPLUS
CN Benzenebutanoic acid, 3-chloro-α,γ-dioxo-4-(phenylmethoxy)-β-(triphenylphosphoranylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L70 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:964135 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 138:24543
TITLE: Preparation of benzyloxyphenyloxobutyrates and related compounds for the treatment of metabolic disorders
INVENTOR(S): ***Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.***
PATENT ASSIGNEE(S): Wellstat Therapeutics Corporation, USA; Bamat, Michael K.
SOURCE: PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100341	A2	20021219	WO 2002-US18388	20020612
WO 2002100341	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450221	AA	20021219	CA 2002-2450221	20020612
US 2003149107	A1	20030807	US 2002-167839	20020612
US 7101910	B2	20060905		
EP 1461323	A2	20040929	EP 2002-744271	20020612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005501012	T2	20050113	JP 2003-503168	20020612
CN 1608055	A	20050420	CN 2002-811881	20020612
BR 2002010383	A	20060404	BR 2002-10383	20020612
US 2004077896	A1	20040422	US 2003-684644	20031014
US 6924314	B2	20050802		
US 2004092518	A1	20040513	US 2003-684735	20031014
US 7041659	B2	20060509		
US 2004092516	A1	20040513	US 2003-685183	20031014
US 6946491	B2	20050920		
US 2004097585	A1	20040520	US 2003-684730	20031014
US 6916848	B2	20050712		

US 2004236100	A1	20041125	US 2003-684660	20031014
US 6858602	B2	20050222		
US 2004267025	A1	20041230	US 2003-684740	20031014
US 7045541	B2	20060516		
ZA 2003009627	A	20050617	ZA 2003-9627	20031211
US 2004242692	A1	20041202	US 2004-865088	20040610
US 2005004115	A1	20050106	US 2004-892950	20040716
US 7012071	B2	20060314		
US 2005090555	A1	20050428	US 2004-5449	20041206
US 2005256333	A1	20051117	US 2005-481042	20050114

PRIORITY APPLN. INFO.:

US 2001-297282P	P	20010612
US 2002-167839	A3	20020612
WO 2002-US18388	W	20020612
US 2003-685183	A3	20031014
US 2004-865088	A1	20040610

OTHER SOURCE(S): MARPAT 138:24543

GI



I

AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF3CO2H in CH2Cl2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

IC ICM A61K

CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28

L70 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:676588 HCAPLUS <<LOGINID::20061121>>

DOCUMENT NUMBER: 135:221312

TITLE: Therapeutic uses of PPAR mediators as ABC-1 expression modulators, and preparation thereof

INVENTOR(S): Jaye, Michael; Duverger, Nicolas; Searfoss, George; Minnich, Anne

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001066098	A2	20010913	WO 2001-EP2482		20010306
WO 2001066098	A3	20020404			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2402315	AA	20010913	CA 2001-2402315		20010306
AU 2001072098	A5	20010917	AU 2001-72098		20010306
BR 2001009107	A	20021203	BR 2001-9107		20010306
EP 1267874	A2	20030102	EP 2001-956185		20010306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004500389	T2	20040108	JP 2001-564751		20010306
NZ 521225	A	20040827	NZ 2001-521225		20010306
ZA 2002007061	A	20031114	ZA 2002-7061		20020903
NO 2002004273	A	20021007	NO 2002-4273		20020906
US 2003220373	A1	20031127	US 2002-237578		20020909
PRIORITY APPLN. INFO.:			US 2000-188323P	P	20000309
			GB 2000-13589	A	20000606
			WO 2001-EP2482	W	20010306

OTHER SOURCE(S): MARPAT 135:221312

AB The invention discloses the use of PPAR mediators, and their pharmaceutical compns., as ATP binding cassette transporter 1 (ABC-1) expression modulators, wherein the PPAR ligand receptor agonists of the invention are useful as inducers of ABC-1 expression. Preparation of compds. of the invention is included. Also disclosed are methods for treating e.g. low levels of HDL.

IC ICM A61K031-00
CC 1-10 (Pharmacology)
Section cross-reference(s): 27, 28, 63
IT 120128-20-3P 123225-56-9P 123225-57-0P 123225-58-1P 123225-59-2P
123225-60-5P 123225-61-6P 123225-63-8P 123225-64-9P 123225-66-1P
123225-67-2P 123225-69-4P 123225-71-8P 123225-72-9P 123225-73-0P
123225-74-1P 123225-75-2P 123225-76-3P 123225-78-5P 123225-80-9P
123225-81-0P 123225-82-1P 123225-94-5P 123225-95-6P 123225-96-7P
123225-97-8P 123225-98-9P 123225-99-0P 123226-00-6P 123226-01-7P
123226-03-9P 123226-04-0P 123226-05-1P 123226-06-2P 123226-07-3P
123226-08-4P 123226-09-5P 123226-10-8P 123226-11-9P 123226-13-1P
123226-14-2P 123226-15-3P 123226-16-4P 123226-17-5P 123226-18-6P
123226-19-7P 123226-20-0P 123226-21-1P 123226-22-2P 123226-23-3P
123226-24-4P 123226-25-5P 123226-26-6P 123226-27-7P 123247-23-4P
123247-24-5P 123247-25-6P 123247-27-8P 123247-28-9P 123692-25-1P
123692-29-5P 123692-36-4P 123692-37-5P 123692-38-6P 123692-39-7P
123692-40-0P 123692-41-1P 123715-60-6P 123791-11-7P 123791-12-8P
123791-15-1P 123791-16-2P 123791-17-3P 123791-18-4P 124993-46-0P
128760-03-2P 128760-51-0P 128760-53-2P 128760-54-3P 128760-55-4P
128760-56-5P 128760-57-6P 128760-58-7P 128760-59-8P 128760-60-1P
128760-61-2P 128760-62-3P 128760-69-0P 128760-70-3P 128760-71-4P

128760-73-6P 128760-74-7P 128760-75-8P 133628-51-0P 133628-56-5P
134138-98-0P 223771-70-8P 223771-74-2P 223771-76-4P 223771-79-7P
223771-81-1P 223772-08-5P 223772-12-1P 223772-14-3P 223772-15-4P
223772-18-7P 223772-26-7P 223772-42-7P 223772-43-8P
223772-45-0P 223772-46-1P 303216-78-6P 303216-82-2P
303216-91-3P 303216-94-6P 303216-98-0P 303217-06-3P 303217-08-5P
303217-10-9P 303217-12-1P 303217-15-4P 303217-18-7P 303217-21-2P
303217-27-8P 303217-33-6P 303217-46-1P 303217-48-3P 303217-76-7P
303217-81-4P 359779-93-4P 359779-94-5P 359779-95-6P
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR mediators as ABC-1 expression modulators, preparation, and therapeutic use)

IT ***223772-45-0P 223772-46-1P***
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR mediators as ABC-1 expression modulators, preparation, and therapeutic use)

RN 223772-45-0 HCAPLUS
CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 HCAPLUS
CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



L70 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:772613 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 133:335164
TITLE: Tri-aryl acid derivatives as PPAR receptor ligands

INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.; Labaudiniere, Richard F.; Zhang, Litao; Caulfield, Thomas J.; Minnich, Anne; Bobko, Mark; Morris, Robert; Groneberg, Robert D.; Mcgarry, Daniel G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000064876	A1	20001102	WO 2000-US11490		20000428
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2371308	AA	20001102	CA 2000-2371308		20000428
EP 1177176	A1	20020206	EP 2000-930210		20000428
EP 1177176	B1	20060419			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY					
BR 2000010126	A	20020226	BR 2000-10126		20000428
HU 200200997	A2	20020729	HU 2002-997		20000428
EE 200100558	A	20021216	EE 2001-558		20000428
NZ 515087	A	20031128	NZ 2000-515087		20000428
AU 782404	B2	20050728	AU 2000-48070		20000428
AT 323678	E	20060515	AT 2000-930210		20000428
RU 2278860	C2	20060627	RU 2001-132081		20000428
PT 1177176	T	20060831	PT 2000-930210		20000428
US 7005440	B1	20060228	US 2000-724496		20001128
ZA 2001008800	A	20030210	ZA 2001-8800		20011024
NO 2001005226	A	20011205	NO 2001-5226		20011025
HR 2001000793	A1	20030228	HR 2001-793		20011026
HK 1047098	A1	20050520	HK 2002-108625		20021129
PRIORITY APPLN. INFO.:			US 1999-131454P	P	19990428
			WO 2000-US11490	W	20000428

OTHER SOURCE(S): MARPAT 133:335164
GI



I



II

AB This invention is directed to triaryl acid derivs. I and their salts, N-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkemyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, NHCONH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonylaminocarbonyl, sulfonylamino, carbamoyl, tetrazolyl, etc.; R1, R3, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-5; p = 0-4; q = 0-6; with numerous provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid underwent a sequence of: (1) Me esterification, (2) benzylic monobromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alkaline hydrolysis with NaOH in aqueous EtOH, to give title compound II.

IC ICM C07D215-14
ICS A61K031-33; A61K031-19; A61P043-00; C07D401-12; C07D401-14; C07D215-18; C07D405-12; C07D263-32; C07D213-30; C07D241-42; C07D277-24; C07D261-08; C07D271-06; C07D277-64

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

IT ***Diabetes mellitus***
(non-insulin-dependent, treatment of; preparation of tri-aryl acid derivs. as PPAR receptor ligands)

IT 120128-20-3P 123225-57-0P 123225-58-1P 123225-59-2P 123225-60-5P
123225-64-9P 123225-66-1P 123225-67-2P 123225-69-4P 123225-71-8P
123225-73-0P 123225-75-2P 123225-76-3P 123225-78-5P 123225-80-9P
123225-81-0P 123225-82-1P 123225-94-5P 123225-95-6P 123225-96-7P
123225-97-8P 123225-98-9P 123225-99-0P 123226-00-6P 123226-01-7P
123226-03-9P 123226-04-0P 123226-05-1P 123226-07-3P 123226-08-4P
123226-09-5P 123226-11-9P 123226-13-1P 123226-14-2P 123226-15-3P
123226-16-4P 123226-17-5P 123226-18-6P 123226-19-7P 123226-20-0P
123226-21-1P 123226-22-2P 123226-23-3P 123226-24-4P 123226-25-5P
123226-26-6P 123226-27-7P 123247-23-4P 123247-24-5P 123247-25-6P
123247-27-8P 123247-28-9P 123692-25-1P 123692-28-4P 123692-29-5P
123692-36-4P 123692-37-5P 123692-38-6P 123692-39-7P 123692-40-0P
123715-60-6P 123791-11-7P 123791-12-8P 123791-15-1P 123791-16-2P

123791-17-3P 123791-18-4P 124993-46-0P 128760-03-2P 128760-51-0P
128760-53-2P 128760-54-3P 128760-55-4P 128760-56-5P 128760-57-6P
128760-59-8P 128760-60-1P 128760-61-2P 128760-62-3P 128760-69-0P
128760-73-6P 128760-74-7P 128760-75-8P 133628-51-0P 133628-56-5P
134138-98-0P 223771-70-8P 223771-76-4P 223771-79-7P 223771-81-1P
223772-08-5P 223772-12-1P 223772-14-3P 223772-15-4P 223772-18-7P
223772-26-7P 223772-42-7P 223772-43-8P ***223772-45-0P***
223772-46-1P 223772-47-2P 303216-72-0P 303216-78-6P
303216-82-2P 303216-84-4P 303216-91-3P 303216-94-6P 303216-98-0P
303217-06-3P 303217-08-5P 303217-10-9P 303217-12-1P 303217-15-4P
303217-18-7P 303217-21-2P 303217-27-8P 303217-33-6P 303217-46-1P
303217-48-3P 303217-73-4P 303217-76-7P 303217-81-4P 303217-83-6P
303217-85-8P 303217-87-0P 303217-89-2P 303217-91-6P 303217-93-8P
303217-95-0P 303217-97-2P 303217-99-4P 303218-01-1P 303218-03-3P
303218-05-5P 303218-07-7P 303218-09-9P 303218-11-3P 303218-13-5P
303218-17-9P 303218-19-1P 303218-21-5P 303218-23-7P 303218-25-9P
303218-27-1P 303218-29-3P 303218-31-7P 303218-33-9P 303218-35-1P
303218-37-3P 303218-39-5P 303218-41-9P 303218-43-1P 303218-45-3P
303218-47-5P 303218-49-7P 303218-51-1P 303218-53-3P 303218-55-5P
303218-57-7P 303218-59-9P 303218-61-3P 303218-63-5P 303218-65-7P
303218-67-9P 303218-69-1P 303218-71-5P 303218-73-7P 303218-75-9P
303218-77-1P 303218-79-3P 303218-81-7P 303218-83-9P 303218-85-1P
303218-87-3P 303218-89-5P 303218-91-9P 303218-93-1P 303218-95-3P
303218-97-5P 303218-99-7P 303219-01-4P 303219-03-6P 303219-05-8P
303219-07-0P 303219-09-2P 303219-11-6P 303219-13-8P 303219-15-0P
303219-17-2P 303219-19-4P 303219-21-8P 303219-23-0P 303219-25-2P
303219-27-4P 303219-29-6P 303219-31-0P 303219-33-2P 303219-35-4P
303219-37-6P 303219-39-8P 303219-41-2P 303219-43-4P 303219-45-6P
303219-47-8P 303219-49-0P 303219-51-4P 303219-53-6P 303219-55-8P
303219-57-0P 303219-59-2P 303219-61-6P 303219-63-8P 303219-65-0P
303219-67-2P 303219-69-4P 303219-71-8P 303219-73-0P 303219-75-2P
303219-77-4P 303219-78-5P 303219-80-9P 303219-82-1P 303219-84-3P
303219-86-5P 303219-88-7P 303219-90-1P 303219-92-3P 303219-94-5P
303219-96-7P 303219-98-9P 303220-00-0P 303220-02-2P 303220-04-4P

RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tri-aryl acid derivs. as PPAR receptor ligands)

IT ***223772-45-0P 223772-46-1P***

RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tri-aryl acid derivs. as PPAR receptor ligands)

RN 223772-45-0 HCAPLUS

CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 HCAPLUS
CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ciba-Geigy Ag	1995			EP 0643045 A	HCAPLUS
Dr Reddy'S Research Fou	1999			WO 9908501 A	HCAPLUS
Glaxo Group Ltd	1997			WO 9731907 A	HCAPLUS
Laboratorios Menarini S	1997			WO 9724331 A	HCAPLUS
Leo Pharmaceutical Prod	1989			WO 8905294 A	HCAPLUS
Merck & Co Inc	1997			WO 9728149 A	HCAPLUS
Merck & Co Inc	1997			WO 9727857 A	HCAPLUS
Merck & Co Inc	1998			WO 9827974 A	HCAPLUS
Ono Pharmaceutical Co L	1999			WO 9907357 A	HCAPLUS
RhOne-Poulenc Rorer Pha	1999			WO 9920275 A	HCAPLUS
Rorer International Ove	1989			WO 8904303 A	HCAPLUS
Rorer International Ove	1989			WO 8912629 A	HCAPLUS
The Upjohn Company	1992			WO 9222533 A	HCAPLUS

L70 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:282096 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 130:320864
TITLE: PPAR-γ-binding quinoline derivatives, their preparation, and their therapeutic use
INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920275	A1	19990429	WO 1998-US21947	19981016

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,

	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2306825		AA	19990429	CA 1998-2306825	19981016
AU 9896961		A1	19990510	AU 1998-96961	19981016
ZA 9809465		A	20000417	ZA 1998-9465	19981016
EP 1030665		A1	20000830	EP 1998-951075	19981016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9814087		A	20001003	BR 1998-14087	19981016
HU 200101022		A2	20011028	HU 2001-1022	19981016
JP 2001520193		T2	20011030	JP 2000-516672	19981016
US 6376512		B1	20020423	US 2000-490897	20000127
NO 2000001962		A	20000616	NO 2000-1962	20000414
BG 104432		A	20001229	BG 2000-104432	20000515
PRIORITY APPLN. INFO.:				US 1997-62318P	P 19971017
				US 1997-65902P	P 19971117
				WO 1998-US21947	W 19981016

OTHER SOURCE(S): MARPAT 130:320864

GI



I

AB A method for mediating the activity of PPAR-γ receptor comprises contacting the PPAR-γ receptor with I [A = O, S, (R1)C=C(R1), bond; B = O, S, SO, SO2, NR1, bond; D = O, S, NR1, (R1)C=C(R1), bond; E = bond; a = 0-2; b = 0, 1; c = 0-4; d = 0-5; e = 0-4; f = 0-5; n = 0-2; R = H; R' = H; R1 = H; R2 = (CH2)qX, or two vicinal R2 taken together with the carbon atoms through which the two vicinal R2 are linked form cycloalkylene, etc.; q = 0-3; X = H]. Preparation of I is described. The compds. may be used to treat cardiovascular conditions, ***diabetes***, ***hyperlipidemia***, ***hypertension***, eating disorders, etc.

IC ICM A61K031-47
ICS A61K031-38; A61K031-35; A61K031-155; A61K031-18

CC 1-12 (Pharmacology)
Section cross-reference(s): 27, 28

IT 114497-47-1P 123225-56-9P 123225-57-0P 123225-58-1P 123225-59-2P
123225-60-5P 123225-61-6P 123225-63-8P 123225-64-9P 123225-69-4P
123225-71-8P 123225-72-9P 123225-76-3P 123225-82-1P 123225-94-5P
123225-95-6P 123225-96-7P 123225-98-9P 123225-99-0P 123226-00-6P
123226-01-7P 123226-03-9P 123226-04-0P 123226-05-1P 123226-06-2P
123226-07-3P 123226-08-4P 123226-09-5P 123226-10-8P 123226-11-9P
123226-13-1P 123226-14-2P 123226-15-3P 123226-16-4P 123226-17-5P

123226-19-7P 123226-20-0P 123226-21-1P 123226-25-5P 123226-27-7P
123247-23-4P 123247-25-6P 123247-27-8P 123247-28-9P 123692-25-1P
123692-29-5P 123692-37-5P 123692-38-6P 123692-39-7P 123791-11-7P
123791-15-1P 124993-46-0P 124993-48-2P 128760-62-3P 128760-70-3P
128760-73-6P 129649-40-7P 223772-08-5P 223772-12-1P 223772-14-3P
223772-15-4P 223772-18-7P 223772-26-7P 223772-42-7P 223772-43-8P
223772-44-9P ***223772-45-0P 223772-46-1P*** 223772-47-2P
223772-48-3P
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR-γ-binding quinoline derivative preparation and therapeutic use)

IT ***223772-45-0P 223772-46-1P***
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR-γ-binding quinoline derivative preparation and therapeutic use)

RN 223772-45-0 HCAPLUS
CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[3-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 223772-46-1 HCAPLUS
CN Benzenebutanoic acid, 3-fluoro-γ-oxo-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Asahi Glass Company Ltd	1996			EP 0709377 A1	HCAPLUS
Merrell Dow Pharmaceuti	1995			WO 9514669 A1	HCAPLUS
Sterne	1965			US 3174901 A	HCAPLUS

L70 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:497460 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 113:97460
TITLE: Preparation of quinoline derivatives useful as lipoxygenase inhibitors and/or leukotriene antagonists
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 348155	A1	19891227	EP 1989-306232	19890620
EP 348155	B1	19990512		
R: DE, ES, FR, GB, IT				
US 4920131	A	19900424	US 1988-209428	19880621
EP 784052	A1	19970716	EP 1997-200638	19890620
EP 784052	B1	20040901		
R: DE, ES, FR, GB, IT				
US 5059610	A	19911022	US 1990-477896	19900420

PRIORITY APPLN. INFO.:

US 1988-209428	A	19880621
US 1987-116420	A2	19871103
US 1987-116428	A2	19871103
US 1987-116597	A2	19871103
WO 1988-US3897	W	19881101
EP 1989-306232	A3	19890620

OTHER SOURCE(S): MARPAT 113:97460
GI



I



II

AB Title compds. I [A = O, S; B = bond, O, S, SO, SO2, NR1, CO, NR1CO, CONR1, CR1:CR1; D = O, S, NR1, CR1:CR1, bond; E = bond, CR1:CR1; a = 0-2; b = 0-1; c = 0-4; d = 0-5, e = 0-4; f = 0-5; n = 0-2; R2 = H, alkyl, OH, alkoxy, CO2H, carbalkoxy, halo NO2, haloalkyl, cyano, acyl; R3 = H, OH, alkoxy, halo, etc.; R1 = H, alkyl, aralkyl; R = (CH2)xX, O(CH2)xX, S(CH2)xX, NR1(CH2)xX; x = 0-3; X = H, alkyl, alkenyl, aryl, alkoxy, amino, cyano, tetrazolyl, CO2R, etc.; (R)2 = (CH2)y with y = 1-4; RR1 = (CH2)z with z = 2-5; (R1)2, RR1 = CHR1; Z = CO2R1, cyano, CONHSO2R4 with R4 = H, alkyl, Ph, etc.; CON(R1)2, OR1, (un)substituted tetrazolyl] were prepared as antiinflammatory and antiallergic agents (no data). Thus, condensation of o-cresol with MeCHBr Co2Et and bromination of the product with NBS gave 2-(BrCH2)C6H4 OCHMeCO2Et, which underwent condensation with 3-(2-quinolinylmethoxy)phenol and basic hydrolysis to give quinoline derivative II. Several addnl. prepns. and numerous I are given.

IC ICM C07D215-14
ICS C07D215-18; C07D401-12; A61K031-47

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

IT 120128-20-3P 123247-27-8P 128760-39-4P 128760-40-7P 128760-41-8P
128760-42-9P 128760-43-0P 128760-44-1P 128760-45-2P 128760-46-3P
128760-47-4P 128760-48-5P 128760-49-6P 128760-50-9P 128760-51-0P
128760-52-1P 128760-53-2P 128760-54-3P 128760-55-4P 128760-56-5P
128760-57-6P 128760-58-7P 128760-59-8P 128760-60-1P 128760-61-2P
128760-62-3P 128760-63-4P 128760-64-5P 128760-65-6P 128760-66-7P
128760-67-8P 128760-68-9P 128760-69-0P 128760-70-3P 128760-71-4P
128760-72-5P 128760-73-6P 128760-74-7P 128760-75-8P 128760-76-9P
128760-86-1P 128760-87-2P ***128784-91-8P*** 128784-92-9P
128805-38-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic and antiinflammatory agent)

IT ***128784-91-8P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic and antiinflammatory agent)

RN 128784-91-8 HCAPLUS

CN Benzenebutanoic acid, 3-fluoro-γ-hydroxy-4-[[4-(2-quinolinylmethoxy)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



→ L70 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:471315 HCAPLUS <<LOGINID::20061121>>
DOCUMENT NUMBER: 93:71315
TITLE: 2-(Substituted benzoyl)propionic acids
INVENTOR(S): Noda, Kanji; Nakagawa, Akira; Hirano, Munehiko; Tsuji, Masayoshi; Ide, Hiroyuki
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55015460	A2	19800202	JP 1978-89591	19780720

PRIORITY APPLN. INFO.: JP 1978-89591 A 19780720

GI



I

AB Seven I (R = H; R1 = Me2CH, H; R2 = H, NO2, Cl; R3 = Me2CH, EtO, cyclopropylmethoxy, allyloxy, etc.), having central-depressant, antiinflammatory, PCA-inhibitory and immunosuppressant activities (no data), were prepared by reacting succinic anhydride (II) with C6H6 derivs., or by reacting I (R = Et, R3 = OH) with R3Br (R3 = cyclopropylmethyl), followed by hydrolysis. Thus, m-(Me2CH)2C6H4 16.2 was added dropwise to II 10 and AlCl3 26.7 g in ClCH2CH2Cl with cooling, and the mixture was stirred 10 h at room temperature to give I (R = R2 = H, R1 = R3 = CHMe2).

IC C07C059-76; C07C079-46; C07C101-44

CC 25-18 (Noncondensed Aromatic Compounds)

IT 74362-69-9P 74362-70-2P 74362-71-3P 74362-72-4P ***74362-73-5P*** 74362-74-6P 74391-08-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT ***74362-73-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 74362-73-5 HCAPLUS

CN Benzenebutanoic acid, 3-chloro-γ-oxo-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L53 ANSWER 1 OF 1 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN.S DCR-905973
DCSE 905973-0-0-0
CN.S 4-(4-Benzyloxy-3-chloro-phenyl)-4-oxo-butyric acid



MF C17 H15 Cl O4
SMF C17 H15 Cl O4 *1; TOTAL *1; TYPE *1
MW 318.7597
SDCN RAECKI

=> d all abeq tech l69 tot

L69 ANSWER 1 OF 1 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-411395 [38] WPIX <<LOGINID::20061121>>
DNC C2004-154379 [38]
TI Use of oxoalkanoates in the manufacture of a medicament for treatment of metabolic disorders e.g. insulin resistance syndrome and diabetes
DC B05
IN HODGE K L; SHARMA S; VON BORSTEL R W; WOLPE S D
PA (WELL-N) WELLSTAT THERAPEUTICS CORP; (HODG-I) HODGE K L; (SHAR-I) SHARMA S; (VBOR-I) VON BORSTEL R W; (WOLP-I) WOLPE S D
CYC 105
PI WO 2004041165 A2 20040521 (200438)* EN 22[0] A61K000-00
AU 2003286728 A1 20040607 (200469) EN
EP 1556085 A2 20050727 (200549) EN A61K047-00
US 20060035970 A1 20060216 (200614) EN
JP 2006507303 W 20060302 (200621) JA 19
AU 2003286728 A8 20051110 (200634) EN A61K047-00
ADT WO 2004041165 A2 WO 2003-US34185 20031028; US 20060035970 A1 Provisional US 2002-423253P 20021101; AU 2003286728 A1 AU 2003-286728 20031028; EP 1556085 A2 EP 2003-777939 20031028; EP 1556085 A2 WO 2003-US34185 20031028; US 20060035970 A1 WO 2003-US34185 20031028; JP 2006507303 W WO 2003-US34185 20031028; JP 2006507303 W JP 2004-550151 20031028; US 20060035970 A1 US 2005-532690 20050426; AU 2003286728 A8 AU 2003-286728 20031028
FDT AU 2003286728 A1 Based on WO 2004041165 A; EP 1556085 A2 Based on WO 2004041165 A; JP 2006507303 W Based on WO 2004041165 A; AU 2003286728 A8 Based on WO 2004041165 A
PRAI US 2002-423253P 20021101

US 2005-532690 20050426
IC ICM A61K005-; A61K047-00
IPCI A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-21 [I,C]; A61K0031-235 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-21 [I,C]; A61K0031-216 [I,A]; A61P0001-00 [I,C]; A61P0001-16 [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A]; A61P0017-00 [I,C]; A61P0017-02 [I,A]; A61P0025-00 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0027-12 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C]; A61P0009-10 [I,A]; A61P0009-12 [I,A]
AB WO 2004041165 A2 UPAB: 20060121
NOVELTY - Treatment of metabolic disorders involves administration of an agent.

DETAILED DESCRIPTION - Treatment of metabolic disorders involves administration of an agent selected from:

(1) 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
(2) methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
(3) ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
(4) 4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
(5) ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
(6) ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
(7) ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
(8) methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
(9) ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
(10) ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
(11) ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
(12) ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
(13) ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
(14) ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
(15) ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate; or
(16) ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate.

ACTIVITY - Antidiabetic; Antiarteriosclerotic; Anorectic; Hypotensive; Antilipemic; Nephrotropic; Neuroprotective; Ophthalmological; Antiulcer; Immunomodulator.

Test details described but no results given.

MECHANISM OF ACTION - None given.

USE - For treatment of metabolic disorders in a subject (such as human) e.g. insulin resistance syndrome and diabetes including Type I Diabetes and Type II Diabetes; for the treatment or reduction in the development of atherosclerosis, arteriosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts associated with diabetes; and for the treatment of cachexia (claimed).

ADVANTAGE - The agent effectively addresses the primary defects of insulin resistance and islet failure with fewer or milder side effects than existing drugs.

MC CPI: B10-C03; B10-F02; B14-D01E; B14-E11; B14-E12; B14-F02B; B14-F06; B14-F07; B14-J01; B14-N03; B14-N10; B14-N12; B14-N17B; B14-S04

C:\Program Files\Stnexp\Queries\trynancy690.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 18
ring nodes :
1 2 3 4 5 6
chain bonds :
3-10 6-7 7-8 8-18 10-11 10-12 12-13 13-14 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-10 4-5 5-6 6-7 7-8 8-18 10-11 10-12 12-13
13-14 14-15 14-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:Atom 18:Atom
Element Count :
Node 18: Limited
C,C6

2nd Structure Searched

C:\Program Files\Stnexp\Queries\zhang690two.str



chain nodes :
7 8 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
3-16 6-7 7-8 8-9 16-17 16-18 18-19 19-20 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 3-16 4-5 5-6 6-7 7-8 8-9 9-10 9-14 10-11 11-12
12-13 13-14 16-17 16-18 18-19 19-20 20-21 20-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom

The 1st structure I searched

Day : Tuesday
Date: 11/21/2006

Time: 10:46:16

PALM INTRANET

Inventor Information for 10/532690

Inventor Name	City	State/Country
HODGE, KIRVIN L. L41	LAUREL	MARYLAND
SHARMA, SHALINI L42	GAITHERSBURG	MARYLAND
VON BORSTEL, REID W. L45	POTOMAC	MARYLAND
WOLPE, STEPHEN D. L46	BOYDS	MARYLAND

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign D

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

CLAIMS

What is claimed is:

1. Use of a biologically active agent in the manufacture of a medicament for treatment of a condition selected from the group consisting of insulin resistance syndrome and diabetes including Type I Diabetes and Type II Diabetes; or for the treatment or reduction in the chance of developing atherosclerosis, arteriosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration or cataracts associated with diabetes; or for the treatment of a condition selected from the group consisting of hyperlipidemia, cachexia, and obesity;

wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;

Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;

Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;

4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;

Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;

Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

2. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver

disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of the biologically active agent effective to treat the condition; wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;

Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;

Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;

4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;

Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;

Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

3. The method of claim 2, wherein the agent is administered orally.

4. The method of claim 2, wherein the subject is a human.

5. The method of claim 4, wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.

6. The method of claim 2, wherein the condition is insulin resistance syndrome or Type II Diabetes.

7. The method of claim 2, wherein the condition is Type 1 Diabetes.

8. The method of claim 2, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.

9. A pharmaceutical composition for use in the treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis, arteriosclerosis and adapted for oral administration, comprising from one milligram to four hundred milligrams of biologically active agent selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;

Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;

Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;

4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;

Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;

Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;

Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;

Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;

Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

10. The invention substantially as described above.

L4 1 ANSWERS HCAPLUS COPYRIGHT 2006 ACS on STN
IC ICM A61K
CC 1-10 (Pharmacology)
TI Oxocarboxylic acids and esters thereof for the treatment of metabolic disorders
ST oxocarboxylic acid metabolic disorder treatment; ester oxocarboxylic acid metabolic disorder treatment
IT Antiarteriosclerotics
(antiatherosclerotics; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Kidney, disease
(diabetic nephropathy; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Nerve, disease
(diabetic neuropathy; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Eye, disease
(diabetic retinopathy; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Liver, disease
(fatty; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Ulcer
(foot; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Autoimmune disease
(insulin-dependent diabetes mellitus; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Diabetes mellitus
(insulin-dependent; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Metabolic disorders
(metabolic syndrome X; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Diabetes mellitus
(non-insulin-dependent; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Drug delivery systems
(oral; oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Antiarteriosclerotics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antiulcer agents
Arteriosclerosis
Atherosclerosis
Cachexia
Cataract
Diabetes mellitus
Drug delivery systems
Human
Hypertension
Hypolipemic agents
Obesity
(oxocarboxylic acids and esters for treatment of metabolic disorders)
IT Hyperlipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(oxocarboxylic acids and esters for treatment of metabolic disorders)

IT Foot
(ulcer; oxocarboxylic acids and esters for treatment of metabolic disorders)

IT 13335-57-4 39208-08-7 53090-45-2 60525-32-8 63539-02-6
73083-19-9 74362-70-2 74362-73-5 77513-51-0 102513-61-1
202577-82-0 371251-24-0 373596-81-7 373596-82-8 373596-84-0
387844-34-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxocarboxylic acids and esters for treatment of metabolic disorders)

ALL ANSWERS HAVE BEEN SCANNED

Zhang 10/911086

Similar structures from inventor

=> d scan

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN ***Benzenebutanoic acid, 4-(cyclohexylmethoxy)-γ-oxo-, ethyl ester (9CI)***
MF C19 H26 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN ***Benzenebutanoic acid, 2-methoxy-γ-oxo-4-(phenylmethoxy)-, methyl ester (9CI)***
MF C19 H20 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN ***Benzenebutanoic acid, 3-chloro-4-(cyclopropylmethoxy)-γ-oxo- (9CI)***
MF C14 H15 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY
IN ***Benzenebutanoic acid, 3-chloro-γ-oxo-4-(phenylmethoxy)-(9CI)***
MF C17 H15 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

Chem Draw



4-(4-benzyloxy-3chlorophenyl)-4-oxobutanoic acid